Evaxion Biotech Stock Forum

$Evaxion Biotech (EVAX.US)$ Evaxion Says Data From Three Separate Clinical Trials Documents The Ability Of The AI-immunology Platform To Select Clinically Relevant Vaccine Targets

$Evaxion Biotech (EVAX.US)$
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
Evaxion Biotech A/S (NASDAQ: EVAX) has reported strong validation of its AI-Immunology™ platform in multiple clinical trials. The company, specializing in AI-powered vaccine development, has gathered evidence from three separate clinical trials demonstrating the platform's ability to select clinically relevant vaccine targets.
Key findings include:
Statistically significant correla...

$Evaxion Biotech (EVAX.US)$ Reuter
2 mins ago
Rcent Clinical Data Confirms Significantly Improved Predictive Power of Evaxion's AI-Immunology™ Platform

$Evaxion Biotech (EVAX.US)$
Evaxion significantly expands vaccine development collaboration with MSD
Agreement provides MSD with options to license Evaxion's preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3
Evaxion will host a conference call and webcast to discuss the agreement on September 27, 2024
COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powe...

$Evaxion Biotech (EVAX.US)$ Evaxion Launches Improved AI-Immunology™ Platform for Vaccine Antigen Prediction

$Evaxion Biotech (EVAX.US)$ down it goes

$Evaxion Biotech (EVAX.US)$
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate
15 out of the 16 patients had a reduction of their tumors (target lesions)
79% of EVX-01's vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches
A positive correlation was observed between the AI-...

$Evaxion Biotech (EVAX.US)$ Evaxion Reports 69% Overall Response Rate in Its Phase 2 Trial on Lead Cancer Vaccine Candidate Evx-01

$Evaxion Biotech (EVAX.US)$
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
• Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate
• 15 out of the 16 patients had reduction of their tumors (target lesions)
• The complete one-year dataset will be presented at the ESMO congress this week and discussed at a webinar...

$Evaxion Biotech (EVAX.US)$
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
Evaxion Biotech A/S (NASDAQ: EVAX) has unveiled improved performance of its key AI-Immunology™ building block, EvaxMHC, at the 32nd Intelligent Systems for Molecular Biology conference. The advancements in EvaxMHC are expected to enhance Evaxion's ability to accurately predict vaccine targets for personalized and precision vaccines in cancer and infect...